PolyPeptide lifts revenue and margins as peptide demand fuels major capacity build-out

PolyPeptide Group AG ( (CH:PPGN) ) has issued an announcement.

PolyPeptide Group reported 2025 revenue of EUR 389.3 million, up 15.6% year-on-year, with EBITDA almost doubling and margins improving as higher production volumes, better operational performance and a favorable product mix took effect. Despite a still negative bottom line driven by adverse financial results, the company turned EBIT positive, strengthened its cash position and continued to benefit from robust demand for peptide-based metabolics, which now account for more than half of sales.

The group accelerated capital expenditure to EUR 110 million, or 28.2% of revenue, to expand global capacity, completing the ramp-up of its large-scale SPPS facility in Belgium and adding new capacity in France and Sweden to support strong customer demand. Management reaffirmed its mid-term ambition to double 2023 revenue by 2028 with EBITDA margins approaching 25%, and issued 2026 guidance for 20–25% revenue growth and a mid- to high-teens EBITDA margin, signaling continued investment-led growth and a bid to consolidate its position in the peptide CDMO market.

The most recent analyst rating on (CH:PPGN) stock is a Hold with a CHF27.00 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.

More about PolyPeptide Group AG

PolyPeptide Group AG is a specialized global contract development and manufacturing organization focused on peptide-based active pharmaceutical ingredients for the biopharmaceutical industry. The company operates a network of manufacturing sites in Europe and the U.S., targeting fast-growing therapeutic areas such as metabolic diseases and supporting customers from development through commercial supply.

Average Trading Volume: 63,975

Technical Sentiment Signal: Sell

Current Market Cap: CHF809.3M

See more data about PPGN stock on TipRanks’ Stock Analysis page.